| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c76ecadad74a1a35270b3e3a34d60f37 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-08 |
| filingDate |
2000-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_038818efe6295ac50df7b6b735b87843
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86e67d70efe1695c3a2a040d112e72a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94cb222a1b4d2d420469dcc6f1d74288
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a922e91f699c9e170b24526d698c5c8 |
| publicationDate |
2002-05-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TR-200103472-T2 |
| titleOfInvention |
Crystalline (2-benzhydryl-1-azabicyclo [2.2.2] oct-3-yl) - (5-iso-propyl-2-methoxybenzyl) -amine citrate polymorphs as NK-1 receptor antagonists. |
| abstract |
The two crystalline polymorphic forms of (2-Benzhydryl-1-azo-bicyclo [2.2.2] oct-3-yl) - (5-isopropyl-2-methoxy benzyl) -amine citrate monohydratin (monohydrates) are Form A p and Form B . A pharmaceutical composition containing at least one of these polymorphs has advantageous stability for the formulation intended to treat acute breastfeeding in a patient receiving chemotherapy. Administration of this pharmaceutical composition is conventionally oral and intravenous, preferably by tablet or capsule. The method of preparing A and B Forms is also explained. |
| priorityDate |
1999-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |